Skip to content

aTyr Pharma ATYR Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
0.0×
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
0.0×
Vor Biopharma logo
Vor BiopharmaVOR
0.5×+0.2×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
8.4×+6.9×

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

Based on the most recent quarter.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's debt-to-equity?
aTyr Pharma (ATYR) reported debt-to-equity of 0.2× in Q1 2026.
How has aTyr Pharma's debt-to-equity changed year-over-year?
aTyr Pharma's debt-to-equity increased by 17.6% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for aTyr Pharma's debt-to-equity?
Over 5 years (2020 to 2025), aTyr Pharma's debt-to-equity has grown at a 21.6% compound annual growth rate (CAGR), from 0.1× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.